Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370165 | 0.93 | KMT2A (0.46) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL31369726 | 0.93 | KMT2A (0.46) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL799719 | 0.93 | KMT2A (0.52) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL793840 | 0.89 | L3MBTL1 (0.45) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL31515414 | 0.89 | L3MBTL1 (0.45) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL119838 | 0.88 | KMT2A (0.44) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL27816574 | 0.86 | L3MBTL1 (0.49) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL31677325 | 0.85 | L3MBTL1 (0.43) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL30966194 | 0.85 | L3MBTL1 (0.43) | KMT2ACHRM4FABP7FABP5L3MBTL1 | |
| SCHEMBL19633062 | 0.85 | L3MBTL1 (0.46) | KMT2AFABP7FABP5L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3653763-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3211126-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2396459-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160369267-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160369267-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9359601-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359601-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20120053091-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053091-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2012-03-01 | — | — | US | disclosed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | disclosed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885CHRM4 4150/4885FABP7 2453/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885CHRM4 4150/4885FABP7 2453/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885CHRM4 4150/4885FABP7 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.